Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)
NCT03493568 · IRCCS San Raffaele · PHASE3 · terminated · last registry update 2024-02-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The futility analysis on 24-week results estimated that there was only 2% probability of verifying the study hypothesis of a higher proportion pat. with no residual viremia through 48w in arm E/C/F/TAF” | – | Registry record, IRCCS San Raffaele |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYP3A4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-12-03Results posted on the registry: Gilead Sciences, Vesatolimod + Cobicistat (NCT05458102)
- 2024-12-03Also stopped (terminated): Gilead Sciences, Vesatolimod + Cobicistat (NCT05458102)
- 2024-10-08Phase 3 first posted: Gilead Sciences, ISL/LEN + Antiretroviral Combinations (NCT06630299)
- 2024-09-19Results posted on the registry: Abivax S.A., ABX464 + Placebo (NCT02735863)
- 2024-08-27Results posted on the registry: Janssen Scientific Affairs, LLC, D/C/F/TAF FDC + TAF/FTC FDC (NCT04442737)
- 2023-12-04Results posted on the registry: R. Kiplin Guy, (+)-SJ000557733 (SJ733) (NCT04709692)
- 2023-12-01Results posted on the registry: National Institutes of Health Clinical Center (CC), Cobicistat + Darunavir/Cobicistat (NCT03864406)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision